GlobalFoundries Inc. Ordinary Shares vs Neurocrine Biosciences Inc — how do they compare? GlobalFoundries Inc. Ordinary Shares trades at $48.04 (market cap $27.51B), while Neurocrine Biosciences Inc trades at $142.16 (market cap $14.36B). The key difference: GlobalFoundries Inc. Ordinary Shares is the larger of the two by market cap, and GlobalFoundries Inc. Ordinary Shares pays a 0.97% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GlobalFoundries Inc. Ordinary Shares for 0 Days and Neurocrine Biosciences Inc for 23 Days on average.
| GFS | NBIX | |
|---|---|---|
Market Cap | $27.51B | $14.36B |
Volume | 10,416,572 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $89.96 | $185.50 |
52-Week Low | $32.24 | $123.10 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $26.80B | $14.37B |
Dividend Yield | 0.97% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
GlobalFoundries is a semiconductor foundry that manufactures chips for other companies. Its technologies serve automotive, communications, industrial, and consumer markets.
Read more on GFS →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →